Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
VSCP's Cash to Debt is ranked higher than
96% of the 513 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. VSCP: No Debt )
VSCP' s 10-Year Cash to Debt Range
Min: 48.76   Max: No Debt
Current: No Debt

Equity to Asset 0.62
VSCP's Equity to Asset is ranked higher than
68% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. VSCP: 0.62 )
VSCP' s 10-Year Equity to Asset Range
Min: -0.97   Max: 0.86
Current: 0.62

-0.97
0.86
Interest Coverage No Debt
VSCP's Interest Coverage is ranked higher than
91% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 365.03 vs. VSCP: No Debt )
VSCP' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -1.01
M-Score: -2.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -32.76
VSCP's Operating margin (%) is ranked higher than
58% of the 488 Companies
in the Global Medical Devices industry.

( Industry Median: 4.77 vs. VSCP: -32.76 )
VSCP' s 10-Year Operating margin (%) Range
Min: -95.59   Max: 6.51
Current: -32.76

-95.59
6.51
Net-margin (%) -32.75
VSCP's Net-margin (%) is ranked higher than
58% of the 488 Companies
in the Global Medical Devices industry.

( Industry Median: 3.24 vs. VSCP: -32.75 )
VSCP' s 10-Year Net-margin (%) Range
Min: -98.53   Max: 4.92
Current: -32.75

-98.53
4.92
ROE (%) -50.94
VSCP's ROE (%) is ranked higher than
53% of the 479 Companies
in the Global Medical Devices industry.

( Industry Median: 4.18 vs. VSCP: -50.94 )
VSCP' s 10-Year ROE (%) Range
Min: -120.47   Max: 10.45
Current: -50.94

-120.47
10.45
ROA (%) -35.90
VSCP's ROA (%) is ranked higher than
56% of the 516 Companies
in the Global Medical Devices industry.

( Industry Median: 1.45 vs. VSCP: -35.90 )
VSCP' s 10-Year ROA (%) Range
Min: -95.8   Max: 6.9
Current: -35.9

-95.8
6.9
ROC (Joel Greenblatt) (%) -1374.00
VSCP's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 512 Companies
in the Global Medical Devices industry.

( Industry Median: 5.87 vs. VSCP: -1374.00 )
VSCP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1378.21   Max: 202.79
Current: -1374

-1378.21
202.79
Revenue Growth (3Y)(%) -6.50
VSCP's Revenue Growth (3Y)(%) is ranked higher than
61% of the 348 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. VSCP: -6.50 )
VSCP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -9.9   Max: 573.1
Current: -6.5

-9.9
573.1
» VSCP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

VSCP Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q2 2014

VSCP Guru Trades in Q2 2014

Jim Simons 11,290 sh (New)
» More
Q3 2014

VSCP Guru Trades in Q3 2014

Jim Simons 14,290 sh (+26.57%)
» More
Q4 2014

VSCP Guru Trades in Q4 2014

Jim Simons 15,890 sh (+11.20%)
» More
» Details

Insider Trades

Latest Guru Trades with VSCP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.70
VSCP's P/B is ranked higher than
86% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 4.25 vs. VSCP: 1.70 )
VSCP' s 10-Year P/B Range
Min: 1   Max: 19.94
Current: 1.7

1
19.94
P/S 0.79
VSCP's P/S is ranked higher than
92% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 3.99 vs. VSCP: 0.79 )
VSCP' s 10-Year P/S Range
Min: 0.79   Max: 85.05
Current: 0.79

0.79
85.05
EV-to-EBIT -1.30
VSCP's EV-to-EBIT is ranked higher than
59% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. VSCP: -1.30 )
VSCP' s 10-Year EV-to-EBIT Range
Min: -4637.1   Max: 802.3
Current: -1.3

-4637.1
802.3
Current Ratio 2.11
VSCP's Current Ratio is ranked higher than
65% of the 516 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. VSCP: 2.11 )
VSCP' s 10-Year Current Ratio Range
Min: 0.05   Max: 6.12
Current: 2.11

0.05
6.12
Quick Ratio 2.11
VSCP's Quick Ratio is ranked higher than
73% of the 516 Companies
in the Global Medical Devices industry.

( Industry Median: 1.93 vs. VSCP: 2.11 )
VSCP' s 10-Year Quick Ratio Range
Min: 0.05   Max: 6.12
Current: 2.11

0.05
6.12
Days Sales Outstanding 63.34
VSCP's Days Sales Outstanding is ranked higher than
81% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 83.08 vs. VSCP: 63.34 )
VSCP' s 10-Year Days Sales Outstanding Range
Min: 41.88   Max: 74.35
Current: 63.34

41.88
74.35

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.67
VSCP's Price/Net Cash is ranked higher than
92% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. VSCP: 7.67 )
VSCP' s 10-Year Price/Net Cash Range
Min: 2.25   Max: 37.41
Current: 7.67

2.25
37.41
Price/Net Current Asset Value 2.51
VSCP's Price/Net Current Asset Value is ranked higher than
96% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. VSCP: 2.51 )
VSCP' s 10-Year Price/Net Current Asset Value Range
Min: 1.54   Max: 20.38
Current: 2.51

1.54
20.38
Price/Tangible Book 2.26
VSCP's Price/Tangible Book is ranked higher than
88% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 7.90 vs. VSCP: 2.26 )
VSCP' s 10-Year Price/Tangible Book Range
Min: 1.31   Max: 23.79
Current: 2.26

1.31
23.79
Price/DCF (Projected) 5.88
VSCP's Price/DCF (Projected) is ranked higher than
79% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. VSCP: 5.88 )
VSCP' s 10-Year Price/DCF (Projected) Range
Min: 1.35   Max: 6.75
Current: 5.88

1.35
6.75
Price/Median PS Value 0.31
VSCP's Price/Median PS Value is ranked higher than
98% of the 579 Companies
in the Global Medical Devices industry.

( Industry Median: 1.30 vs. VSCP: 0.31 )
VSCP' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 3.53
Current: 0.31

0.36
3.53
Earnings Yield (Greenblatt) -76.90
VSCP's Earnings Yield (Greenblatt) is ranked lower than
67% of the 497 Companies
in the Global Medical Devices industry.

( Industry Median: 1.30 vs. VSCP: -76.90 )
VSCP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3
Current: -76.9

0.1
3

Business Description

Industry: Medical Devices » Medical Devices
Compare:PAYX, AHEXY, RANJY, TMH, HAYPY » details
VirtualScopics Inc. is a provider of quantitative imaging for clinical trials serving the pharmaceutical, biotechnology and medical device industries. The Company has developed a software platform for analysis and modeling of both structural and functional medical images. This platform provides information about the biological activity of drugs and devices in clinical trial patients. VirtualScopics is an imaging core lab providing central reads and quantitative imaging solutions for drug and medical device clinical trials for the areas of oncology, rheumatoid arthritis, osteoarthritis, neurology, and cardiovascular studies utilizing MRI, PET, CT, Ultrasound, and X-ray imaging modalities. The Company's image-based measurement and visualization tools enable automated and reproducible measurement of minute changes that occur in anatomic structures in musculoskeletal, oncological, cardiological and neurological diseases. The Company's image analysis provides a degree of accuracy and reproducibility that cannot be duplicated by manual techniques. The Company's quantitative imaging replaces subjective evaluation. It has developed a suite of patented semi-automated tools for the identification and measurement of carotid plaques. Evaluating diseases such as multiple sclerosis (MS), epilepsy, and Alzheimer's requires the identification and measurement of neurological structures and lesions. The Company's competition is largely comprised of a limited number of university research centers that are working on developing the next generation of image analysis tools. The Company's main customers are Novartis, Merck Serono and Amgen. The Company's main competitors are clinical research organizations (CROs) providing clinical trial services to pharmaceutical companies. Healthcare in the United States is heavily regulated by the federal government, and by state and local governments.
» More Articles for VSCP

Headlines

Articles On GuruFocus.com
VirtualScopics Receives Further Extension to Regain Compliance with Nasdaq Dec 24 2008 

More From Other Websites
IXICO’s Imaging Data and Query Management Platform, TrialTracker™, operational at VirtualScopics... May 01 2015
VirtualScopics, Inc. Schedules First Quarter 2015 Financial Results Press Release, Conference Call... Apr 23 2015
VIRTUALSCOPICS, INC. Financials Apr 07 2015
VIRTUALSCOPICS, INC. Files SEC form 10-K, Annual Report Mar 31 2015
IXICO and VirtualScopics Enter Collaboration Agreement with Micron Mar 12 2015
IXICO and VirtualScopics Enter Collaboration Agreement with Micron Mar 11 2015
VirtualScopics, Inc. And IXICO plc Enter Into A Collaboration Agreement With Micron, Inc. Mar 10 2015
VIRTUALSCOPICS, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers Mar 05 2015
VIRTUALSCOPICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation... Feb 27 2015
VirtualScopics, Inc. Reports Fourth Quarter And Year End 2014 Financial Results Feb 26 2015
VirtualScopics, Inc. to Host Fourth Quarter and Fiscal Year 2014 Earnings Conference Call and... Feb 25 2015
VirtualScopics, Inc. Schedules Fourth Quarter And Year End 2014 Financial Results Press Release,... Feb 13 2015
VIRTUALSCOPICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Feb 11 2015
Andrew Levitch And Michael Woehler, Ph.D. Join Virtualscopics, Inc.'s Board Of Directors; David... Feb 11 2015
License of TrialTracker to VirtualScopics Jan 14 2015
IXICO and VirtualScopics Hold First Scientific Advisory Board Meeting Jan 13 2015
VirtualScopics Licences IXICO's Proprietary TrialTracker™ Digital Platform Dec 16 2014
IXICO Licences its Proprietary TrialTracker™ Digital Platform to VirtualScopics Dec 16 2014
IXICO licensing deal with VirtualScopics Dec 16 2014
IXICO licensing deal with VirtualScopics Dec 16 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK